有效的小分子逆转剂用于抗凝药Fondaparinuxuxux
Daniel Carbajo1, Yolanda Pérez2, Gabriela F Castelo1
1Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia, IQAC-CSIC, Jordi Girona 18-26, 08034 Barcelona, Spain.
ACS pharmacology & translational science
|May 15, 2025
概括
新的精氨酸衍生小分子有效地逆转了 fondaparinux 的抗凝活性. 这些新型化合物在体外和体外表现出强烈的抗毒剂作用,为管理与芬达巴林克斯治疗相关的出血风险提供了有希望的解决方案.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 药用化学 医学化学
背景情况:
- 合成糖抗凝剂Fondaparinux对肝素具有优势,但缺乏有效的解毒剂.
- 失控出血是与 fondaparinux 使用相关的重大风险,限制其临床应用.
- 现有的抗药物,如前胺,对 fondaparinux 是无效的.
研究的目的:
- 开发和描述新型的小分子抗药物用于 fondaparinux.
- 评估精氨酸衍生物作为 fondaparinux 逆转剂的疗效.
- 调查这些新型抗药的作用机制.
主要方法:
- 血液凝固的体外酶分析.
- 在刚提取的老鼠血液中进行了ex vivo测试.
- 光光谱,NMR光谱和分子动力学模拟以研究分子相互作用.
主要成果:
- 两个精氨酸衍生物,3AC和3FF有效地逆转了 fondaparinux 的抗凝剂活性.
- 这些衍生品在与ciraparantag和protamine相比,显示出更高的功效.
- 活体研究证实了它们在全血中的有效性,机械学研究表明它们与 fondaparinux 有着强烈的结合.
结论:
- 精子衍生物3AC和3FF是 fondaparinux 的强大和有效的抗剂.
- 这些小分子为宏分子抗药提供了一个有希望的替代品.
- 它们代表了在治疗源自 fondaparinux 和潜在的其他肝类药物的出血并发症方面取得的重大进展.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
573
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
573
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
422
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
422
01:16Clot Retraction and Fibrinolysis
3.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.0K
01:19Depolarizing Blockers: Pharmocokinetics
297
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
297
01:13Therapeutic Index
4.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.0K